<DOC>
	<DOCNO>NCT02208843</DOCNO>
	<brief_summary>The objective single-arm , open-label trial ass efficacy safety afatinib second line treatment patient locally advanced metastatic non-small cell lung cancer ( NSCLC ) harbour common EGFR mutation fail first-line platinum-based chemotherapy demonstrate efficacy safety comparable result see previous trial .</brief_summary>
	<brief_title>Afatinib Second-line Therapy Lung Cancer With Epidermal Growth Factor Receptor ( EGFR ) Mutation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : 1 . Pathologically confirm diagnosis Stage IIIB ( cytologically proven pleural effusion pericardial effusion ) Stage IV adenocarcinoma lung . Patients mixed histology eligible adenocarcinoma predominant histology . 2 . Documented EGFR mutation ( L858R and/or Deletion 19 ) know EGFR mutation . 3 . Measureable disease accord RECIST 1.1 . 4 . Radiologically confirm progression recurrence disease follow first line therapy platinumbased chemotherapy regimen . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 . 6 . Adequate organ function . Exclusion criterion : 1 . More one line prior therapy disease . 2 . Previously receive less 3 cycle platinumbased chemotherapy due toxicity and/or intolerance treatment . 3 . Previous treatment EGFR target Tyrosine Kinase Inhibitor ( TKI ) antibody . 4 . Known preexist interstitial lung disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>